The purpose of this study is to compare disease free survival when adding immunotherapy to initial chemotherapy vs immunotherapy only in maintenance therapy. You must be diagnosed with stage 2 or stage 3 non-small cell lung cancer (NSCLC).
Contact phoneTracy Bellefeuil | 517.364.2835
Principal investigatorDr. Gordan Srkalovic, MD, PhD
Trial SubCategoryNon-Small Cell Lung